Work

Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

Year: 2017

Type: article

Source: The American Journal of Cardiology

DOI: 10.1016/j.amjcard.2017.07.095

Authors: Sean T. Chen, Anne S. Hellkamp, Richard C. Becker, Scott D. Berkowitz, Günter Breithardt, Keith A.A. Fox, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Daniel E. Singer, Manesh R. Patel

Institutions: Duke University, Duke Clinical Research Institute, University of Cincinnati, Bayer (United States), University of Münster, Edinburgh Royal Infirmary, University of Edinburgh, Heidelberg University, Mount Sinai Hospital, The University of Western Australia, Stanford Medicine, Stanford University, Janssen Research & Development (United States), Harvard University, Massachusetts General Hospital

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bayer HealthCare, Johnson and Johnson Pharmaceutical Research and Development

OpenAlex ID: W2744533093

FWCI: 1.713

Cites: 7

Cited by: 11

Related to: 10